Cartesian Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNAC research report →
Range $16 – $25
Price Chart
About the company
Cartesian Therapeutics, Inc. , a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
- CEO
- Carsten Brunn
- IPO
- 2016
- Employees
- 75
- HQ
- Frederick, MD, US
Get TickerSpark's AI analysis on RNAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $303.51M
- P/E
- -1.74
- PEG
- 0.01
- P/S
- 205.49
- P/B
- -2.43
- EV/EBITDA
- -1.39
- Div Yield
- 0.00%
- Gross Margin
- -766.42%
- Op Margin
- -6679.69%
- Net Margin
- -10422.48%
- ROE
- 141.41%
- ROIC
- -30.78%
Latest fiscal year · YoY change
- Revenue
- $2.80M-92.8%
- Gross Profit
- $2.80M-92.8%
- Op Income
- $-86,705,000
- Net Income
- $-130,302,000-68.3%
- EPS
- $-5.02-67.9%
- OCF Growth
- -212.3%
- FCF Growth
- -142.3%
- 52W High
- $11.80
- 52W Low
- $5.60
- 50D MA
- $8.86
- 200D MA
- $7.55
- Beta
- 0.56
- RSI (14)
- 72
- Avg Volume
- 267.74K
No earnings-call transcripts are available for RNAC yet.
- Free Float
- 36.2%
- Shares Outstanding
- 29.38M
- Float Shares
- 10.63M
of shares held by institutions
70 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 541.23K | ▲ 20.51K |
| Two Sigma Advisers, LP | 24.81K | ▲ 24.81K |
| Quest Partners LLC | 6.92K | 0 |
| Cwm, LLC | 4.64K | ▲ 4.45K |
| California State Teachers Retirement System | 567 | ▼ 78 |
Held by 78 ETFs
Biggest fund positions in RNAC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Hoge Elizabeth | other | 758,001 |
| Apr 2, 26 | Hoge Elizabeth | other | 22,740.03 |
| Apr 2, 26 | Kalayoglu Murat | other | 758,001 |
| Apr 2, 26 | Kalayoglu Murat | other | 22,740.03 |
| Mar 13, 26 | Singer Michael | other | 6,555 |
| Jan 6, 26 | Brunn Carsten | sell | 23,766 |
| Jan 6, 26 | Miljkovic Milos | sell | 3,573 |
| Jan 6, 26 | Davis Blaine | sell | 10,591 |
| Jan 2, 26 | DeSilva Nishan M | other | 2,600 |
| Jan 2, 26 | DeSilva Nishan M | other | 7,800 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RNAC coverage
Recent articles, reports, and earnings notes.
No research on RNAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNAC report →Cartesian Therapeutics Announces New Employment Inducement Grants
globenewswire.com · Aug 7
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 6
Cartesian Therapeutics Announces New Employment Inducement Grants
globenewswire.com · Jul 2
New Strong Sell Stocks for July 1st
zacks.com · Jul 1
Cartesian Therapeutics Announces New Employment Inducement Grant
globenewswire.com · Jun 12
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
benzinga.com · Jun 9
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
globenewswire.com · Jun 9
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
globenewswire.com · May 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.